Boehringer Ingelheim expands equine health pipeline with acquisition of Evax AG

Boehringer Ingelheim announced today that it has acquired Evax AG, a Swiss biotech company focused on equine health. Founded more than a decade ago at the University of Zurich, Evax has been exploring the use of therapeutic vaccines to address significant unmet needs in horses, particularly for the treatment of allergic skin diseases. “We’re excited to have the potential […]